2023
DOI: 10.1002/jcla.24892
|View full text |Cite
|
Sign up to set email alerts
|

Adenylate kinase 2 is a biomarker related to the prognosis of glioma and the immune microenvironment

Abstract: Gliomas, including lower-grade glioma (LGG) and glioblastoma (GBM), account for the vast majority of primary malignant tumors affecting the brain and other parts of the central nervous system (CNS). 1 They have received significant attention because of their dismal prognosis and poor treatment outcomes. In 2021, the WHO released the fifth edition of the WHO Classification of Tumors of the Central Nervous System (WHO CNS5), in which the glioma grading system includes four grades, WHO 1 to 4. 2 Despite the avail… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
3

Relationship

1
2

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 35 publications
0
2
0
Order By: Relevance
“…Gliomas with higher expression of AK2 had a worse prognosis. Experimental downregulation of AK2 in vitro in glioma tissue cultures reduced cell proliferation, migration, and colony formation [56].…”
Section: Uniprotmentioning
confidence: 93%
“…Gliomas with higher expression of AK2 had a worse prognosis. Experimental downregulation of AK2 in vitro in glioma tissue cultures reduced cell proliferation, migration, and colony formation [56].…”
Section: Uniprotmentioning
confidence: 93%
“…AK2 encodes adenosine kinase 2, an enzyme that plays an important role in cells and is mainly involved in cellular energy metabolism and signal transduction. [17] At present, the direct link between AK2 and asthma has not been clarified. However, we can make some possible inferences.…”
Section: Disscussmentioning
confidence: 99%